Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00096083 | Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer | PHASE2 | COMPLETED | 56 | — | — | Sep 1, 2004 | Aug 1, 2012 | Oct 23, 2013 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Melphalan Administration PHP | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| isolated perfusion | DRUG | - |
| melphalan | DRUG | - |
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed hepatic malignancy * Unresectable disease * Disease predominantly in the parenchyma of the liver * One of the following primary tumor histologies: * Adenocarcinoma of gastrointestinal or other origin * Neuroendocri...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |